Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3058332 | 0.83 | SCN10A (0.50) | ALDH1A1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL3061269 | 0.83 | CNR2 (0.50) | ALDH1A1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL3062444 | 0.83 | MAPT (0.53) | ALDH1A1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL3058786 | 0.82 | ACKR3 (0.50) | ALDH1A1KMT2ASMN1; SMN2MAPTGRM5 | |
| SCHEMBL3059672 | 0.82 | CNR2 (0.60) | ALDH1A1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL3062346 | 0.81 | ACKR3 (0.49) | ALDH1A1KMT2ASMN1; SMN2MAPTGRM5 | |
| SCHEMBL3054245 | 0.81 | CNR2 (0.48) | ALDH1A1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL3054262 | 0.79 | ALDH1A1 (0.62) | ALDH1A1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL13088944 | 0.79 | GRM4 (0.52) | ALDH1A1KMT2ASMN1; SMN2GRM4MAPT | |
| SCHEMBL3059908 | 0.79 | SMN1; SMN2 (0.65) | ALDH1A1CYP1A2CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261760-A1 | EP2 Receptor Agonists | ASTERAND UK LIMITED (GB) | 2010-10-14 | — | — | US | disclosed |
| US-20100261760-A1 | EP2 Receptor Agonists | ASTERAND UK LIMITED (GB) | 2010-10-14 | — | — | US | disclosed |
| US-20100261760-A1 | EP2 Receptor Agonists | ASTERAND UK LIMITED (GB) | 2010-10-14 | — | — | US | disclosed |
| US-7803841-B2 | EP2 receptor agonists | ASTERAND UK LIMITED (GB) | 2010-09-28 | — | — | US | disclosed |
| US-7803841-B2 | EP2 receptor agonists | ASTERAND UK LIMITED (GB) | 2010-09-28 | — | — | US | disclosed |
| US-7803841-B2 | EP2 receptor agonists | ASTERAND UK LIMITED (GB) | 2010-09-28 | — | — | US | disclosed |
| US-7662839-B2 | EP2 receptor agonists | ASTERAND UK LIMITED (GB) | 2010-02-16 | — | — | US | disclosed |
| US-7662839-B2 | EP2 receptor agonists | ASTERAND UK LIMITED (GB) | 2010-02-16 | — | — | US | disclosed |
| US-7662839-B2 | EP2 receptor agonists | ASTERAND UK LIMITED (GB) | 2010-02-16 | — | — | US | disclosed |
| US-20090298899-A1 | EP2 RECEPTOR AGONISTS | ASTERAND UK LIMITED | 2009-12-03 | — | — | US | disclosed |
| US-20090298899-A1 | EP2 RECEPTOR AGONISTS | ASTERAND UK LIMITED | 2009-12-03 | — | — | US | disclosed |
| US-20080119526-A1 | EP receptor (for which the endogenous ligand is prostaglandin E2, PGE2); dysmenorrhoea, preterm labour, glaucoma, immune disorders, inflammatory disorders; e.g. {4-[(5-Phenyl-furan-2-carbonyl)-amino]-phenyl}-acetic acid | PHARMAGENE LABORATORIES LIMITED (GB) | 2008-05-22 | — | — | US | disclosed |
| US-20080119526-A1 | EP receptor (for which the endogenous ligand is prostaglandin E2, PGE2); dysmenorrhoea, preterm labour, glaucoma, immune disorders, inflammatory disorders; e.g. {4-[(5-Phenyl-furan-2-carbonyl)-amino]-phenyl}-acetic acid | PHARMAGENE LABORATORIES LIMITED (GB) | 2008-05-22 | — | — | US | disclosed |
| US-20080119526-A1 | EP receptor (for which the endogenous ligand is prostaglandin E2, PGE2); dysmenorrhoea, preterm labour, glaucoma, immune disorders, inflammatory disorders; e.g. {4-[(5-Phenyl-furan-2-carbonyl)-amino]-phenyl}-acetic acid | PHARMAGENE LABORATORIES LIMITED (GB) | 2008-05-22 | — | — | US | disclosed |
| US-7326732-B2 | EP2 receptor agonists | PHARMAGENE LABORATORIES LIMITED (GB) | 2008-02-05 | — | — | US | disclosed |
| US-7326732-B2 | EP2 receptor agonists | PHARMAGENE LABORATORIES LIMITED (GB) | 2008-02-05 | — | — | US | disclosed |
| US-7326732-B2 | EP2 receptor agonists | PHARMAGENE LABORATORIES LIMITED (GB) | 2008-02-05 | — | — | US | disclosed |
| EP-1723132-A1 | EP2 RECEPTOR AGONISTS | ASTERAND UK LIMITED (GB) | 2006-11-22 | — | — | EP | disclosed |
| US-20050256170-A1 | EP receptor (for which the endogenous ligand is prostaglandin E2, PGE2); e.g. (4-[(5-Phenyl-furan-2-carbonyl)-amino]-phenyl)-acetic acid or 5-Phenyl-furan-2-carboxylic acid [3-(1H-tetrazol-5-yl)-phenyl]-amide; dysmenorrhoea, preterm labour, glaucoma, immune disorders, inflammatory disorders | ASTERAND, INC. | 2005-11-17 | — | — | US | disclosed |
| WO-2005080367-A1 | EP2 RECEPTOR AGONISTS | PHARMAGENE LABORATORIES LIMITED (GB) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298899-A1 | EP2 RECEPTOR AGONISTS | PTGER2, PTGER1, TBXA2R | ALDH1A1 2212/4885CYP1A2 672/4885CYP3A4 1979/4885 |
| US-20080119526-A1 | EP receptor (for which the endogenous ligand is prostaglandin E2, PGE2); dysmenorrhoea, preterm labour, glaucoma, immune disorders, inflammatory disorders; e.g. {4-[(5-Phenyl-furan-2-carbonyl)-amino]-phenyl}-acetic acid | PTGER3, PTGER4, PTGES3 | ALDH1A1 1302/4885CYP1A2 1048/4885CYP3A4 1350/4885 |
| US-20100261760-A1 | EP2 Receptor Agonists | PTGER2, PTGER1, TBXA2R | ALDH1A1 2212/4885CYP1A2 672/4885CYP3A4 1979/4885 |
| US-20050256170-A1 | EP receptor (for which the endogenous ligand is prostaglandin E2, PGE2); e.g. (4-[(5-Phenyl-furan-2-carbonyl)-amino]-phenyl)-acetic acid or 5-Phenyl-furan-2-carboxylic acid [3-(1H-tetrazol-5-yl)-phenyl]-amide; dysmenorrhoea, preterm labour, glaucoma, immune disorders, inflammatory disorders | PTGER3, PTGER1, PTGER4 | ALDH1A1 1588/4885CYP1A2 1022/4885CYP3A4 1510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.